Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Patients Less Than 1 Year of Age
Status:
Recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
A Phase 1/2, Open-label, Multicenter, Non-randomized Study to Assess the Safety,
Tolerability, Pharmacokinetics and Efficacy of Burosumab in Paediatric Patients from Birth to
Less than 1 Year of Age with X-linked Hypophosphatemia (XLH)